适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •patients who have low performance status
研究者
相似试验
已完成
不适用
A Blinded, Placebo-Controlled, Randomized, Single Ascending Dose Study in Healthy Male Subjects to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-37822681psychosis10039628NL-OMON30850Johnson & Johnson Pharmaceutical24
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary SyndromeThe ATLAS ACS 2 TIMI 51 Trial (The second trial of Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome)Amendment INT-2 - The ATLAS ACS 2 TIMI 51 TrialAcute Coronary Syndrome (ACS)MedDRA version: 9.1Level: LLTClassification code 10051592Term: Acute coronary syndromeEUCTR2008-002708-25-SKJanssen-Cilag International N.V.16,000
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary SyndromeThe ATLAS ACS 2 TIMI 51 Trial (The second trial of Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome)Amendment INT-1 - The ATLAS ACS 2 TIMI 51 TrialEUCTR2008-002708-25-HUJanssen-Cilag International N.V.16,000
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary SyndromeThe ATLAS ACS 2 TIMI 51 Trial (The second trial of Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome)Amendment INT-2 - The ATLAS ACS 2 TIMI 51 TrialAcute Coronary Syndrome (ACS)MedDRA version: 9.1Level: LLTClassification code 10051592Term: Acute coronary syndromeEUCTR2008-002708-25-SEJanssen-Cilag International N.V.16,000
已完成
3 期
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary SyndromeCTRI/2011/08/001941Johnson Johnson Pharmaceutical Research Development LLC15,527